PMV Pharmaceuticals Appoints Steven H. Holtzman to the Board of Directors
Accelerating the Discovery and Development of Novel Cancer and Infectious
DOYLESTOWN, Pa. -- April 30, 2014
PMV Pharmaceuticals, Inc., announced the appointment of renowned biotechnology
business leader, Steven Holtzman to the board of directors. Mr. Holtzman’s
appointment brings the total board to five members as he joins current members
Arnold Levine, Ph.D., David Mack, Ph.D., Arnold Oronsky, Ph.D. and Douglas
“The addition of Steve Holtzman to our Board provides us with important
strategic insights as we look to develop our cancer and infectious disease
therapeutics. Steve’s proven business and commercial expertise will be of
great value as our product portfolio continues to mature,” David Mack, Ph.D.,
President and CEO of PMV Pharmaceuticals said.
PMV Pharma is pioneering the discovery and development of p53 targeted small
molecule drugs for the treatment of cancer and infectious disease. Founded by
p53 thought leader Dr. Arnold Levine and world-renowned virologist Dr. Thomas
Shenk, in collaboration with co-founder Dr. David Mack, PMV Pharma possesses
unique insights into p53 biology and the discovery of selective modulators of
p53 and its pathway.
p53’s importance in human biology is profound: it is the most commonly mutated
protein in human cancers with more than half of all tumors containing mutant
p53. It is also a key cellular defense against viral infection and is known to
suppress the replication of numerous viruses.
“PMV Pharmaceuticals has assembled a world-class team. Now is the time to
apply the knowledge accumulated over decades of p53 research into the
discovery and development of life changing medicines. The era of big biology
is upon us, and I expect PMV Pharma to be a major player in a new generation
of medicines,” Steve Holtzman said.
Steve Holtzman currently serves as Executive Vice President, Corporate
Development for Biogen Idec where he is responsible for Business Development
and M&A, and Program Leadership & Management of the company’s late-stage
product candidates and marketed products. Prior to joining Biogen Idec, Mr.
Holtzman served as the Founder, CEO and Chair of the Board of Directors of
Infinity Pharmaceuticals, Inc., a cancer drug discovery and development
company. Mr. Holtzman was an early leader and Chief Business Officer of
Millennium Pharmaceuticals, Inc., now a subsidiary of Takeda Pharmaceuticals.
Prior to joining Millennium, he was a Founder, a member of the Board, and the
Executive Vice President of DNX Corporation, the first commercial enterprise
devoted to the development of agricultural, biomedical and pharmaceutical
applications of transgenic technology.
Steve received his B.A. in Philosophy (1976) from Michigan State University
and his B.Phil. graduate degree in Philosophy (1979) from Corpus Christi
College, Oxford University, which he attended as a Rhodes Scholar.
About PMV Pharma
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the
treatment of cancer and infectious disease. Bringing together leaders in the
field to utilize over three decades of p53 biology, PMV Pharma combines unique
biological understanding with pharmaceutical development focus. PMV Pharma
received initial funding from premier venture capital firm InterWest Partners
and has corporate operations in Redwood City, California and Research and
Development in Doylestown, Pennsylvania.
For additional information about PMV Pharma, its scientific platform,
management team, board of directors and scientific advisory board, please
PMV Pharma, Inc.
David Mack, Ph.D., 650-241-2822
President & CEO
Press spacebar to pause and continue. Press esc to stop.